Darolutamide: Mechanism of Action, Indications and Important Notes
Darolutamide is an active substance from the group of second-generation androgen receptor inhibitors used in oncology for certain forms of prostate cancer. It was developed to specifically inhibit the androgen receptor signalling pathway, which plays a central role in the growth of prostate cancer cells. Darolutamide is characterised by a structurally unique composition that may be associated with a different side-effect profile compared to other androgen receptor inhibitors such as enzalutamide and apalutamide. In particular, its lower penetration of the blood-brain barrier is discussed as a potential advantage with regard to neurological side effects.
Mechanism of Action
Prostate cancer cells frequently carry androgen receptors in early stages, which are activated by testosterone and dihydrotestosterone and drive cell growth. Darolutamide acts as a competitive antagonist at the androgen receptor: it displaces androgens from their binding site on the receptor and thus prevents receptor activation. In addition, darolutamide inhibits translocation of the androgen-receptor complex into the cell nucleus and thus the activation of androgen-dependent target genes.
Compared to enzalutamide, darolutamide shows a reduced tendency to cross the blood-brain barrier. The blood-brain barrier protects the brain from the entry of many substances from the blood. Because darolutamide crosses this barrier less readily, its concentration in the brain is lower. This is regarded as a possible reason why central side effects such as seizures or cognitive impairment occurred less frequently in clinical studies. However, the data on this direct comparison have not yet been conclusively evaluated.
Darolutamide exists as a mixture of two stereoisomers (ORM-16497 and ORM-16555), both of which are pharmacologically active and contribute differently to the overall picture of efficacy.
Indications
Non-Metastatic Castration-Resistant Prostate Cancer
The primary approval of darolutamide covers non-metastatic castration-resistant prostate cancer (nmCRPC) in adults at high risk of developing distant metastases. High risk is generally defined on the basis of PSA doubling time: a rapidly rising PSA value despite castration-level testosterone indicates aggressive disease. Darolutamide is used in this indication together with ongoing androgen deprivation therapy. Clinical studies have shown that darolutamide can prolong metastasis-free survival and overall survival in this patient group.
Metastatic Hormone-Sensitive Prostate Cancer
A further approval covers metastatic hormone-sensitive prostate cancer (mHSPC), i.e. patients whose tumour still responds to androgen suppression but has already formed metastases. Darolutamide is used in this indication in combination with androgen deprivation therapy and docetaxel (a chemotherapy agent). The triple combination has shown an additional survival benefit in clinical studies compared to androgen deprivation alone or in combination with docetaxel.
Dosage Form and Dosing
Darolutamide is available as film-coated tablets for oral administration. The usual dose is 600 mg twice daily, giving a total of 1200 mg per day. Unlike other androgen receptor inhibitors such as enzalutamide, which are taken once daily, darolutamide requires twice-daily administration. Darolutamide should be taken with food, as absorption is improved thereby. The tablets can be divided but should not be crushed or chewed.
Important Notes
Darolutamide is not a potent inducer of CYP3A4, meaning it causes fewer interactions through enzyme induction compared to enzalutamide. Nevertheless, clinically relevant interactions exist with certain medications, particularly those that inhibit or induce P-glycoprotein or BCRP (breast cancer resistance protein). A thorough medication history before starting therapy is also important with darolutamide.
In cases of impaired liver or kidney function, dose adjustment may be required. The treating oncology team assesses this based on the available laboratory findings and kidney function parameters.
Adverse Effects
The side-effect profile of darolutamide differs in some respects from that of other androgen receptor inhibitors:
- Fatigue and general weakness are common complaints
- Hot flushes as a consequence of low androgen levels occur frequently
- Limb pain and muscle pain have been reported
- Nausea is possible
- Seizures were observed less frequently in clinical studies than with enzalutamide, which is attributed to lower CNS penetration. The risk exists in principle, however.
- Cognitive changes such as memory impairment occurred less frequently in studies than under enzalutamide
- Elevated liver enzyme levels have been described and require monitoring
- Skin rash is possible
- Bone fractures and falls, also in connection with androgen deprivation-related bone density loss
Drug Interactions
Darolutamide may be a substrate and a weak inhibitor of P-glycoprotein and BCRP. Concomitant intake of potent inducers of CYP3A4 and P-glycoprotein (such as rifampicin, certain antiepileptics) can reduce exposure to darolutamide and impair its efficacy. Conversely, darolutamide can increase exposure to certain substrates of P-glycoprotein and BCRP. The treating medical team will provide information on specific interactions in individual cases.
Darolutamide on Sanoliste
On Sanoliste you will find urologists and oncologists who specialise in the treatment of prostate cancer and can provide competent information on questions regarding modern androgen receptor inhibitors. Therapy with darolutamide requires regular follow-up checks, including of PSA, imaging and general health status.
The information on this page is for general information purposes only and does not replace consultation with a physician. Darolutamide is a prescription-only medicine and may only be taken under medical supervision.
Frequently Asked Questions about Darolutamide
What distinguishes darolutamide from enzalutamide?
Both active substances are second-generation androgen receptor inhibitors with similar principles of action. The essential structural and pharmacological difference lies in the lower penetration of the blood-brain barrier by darolutamide. In clinical studies, seizures and cognitive impairment occurred less frequently with darolutamide than with enzalutamide, which is attributed to this difference. Furthermore, darolutamide is not a potent CYP3A4 inducer, which reduces the interaction potential with other medications. For patients with concerns about neurological side effects or polypharmacy, darolutamide may be an alternative worth discussing. The final treatment choice is made by the treating oncologist in consultation with the patient.
Why is darolutamide taken twice daily?
Compared to enzalutamide, darolutamide has a shorter half-life in the blood. To ensure a stable drug level over 24 hours, two daily administrations are required. This dosing requirement is one aspect that can influence treatment adherence. At the same time, twice-daily administration offers the advantage that a missed dose results in a smaller error than with a once-daily dose. In general: missed doses should be taken as soon as possible, unless it is almost time for the next dose. Doubling doses is not recommended.
What monitoring is required during darolutamide therapy?
During therapy with darolutamide, regular monitoring is necessary, including PSA measurements to assess treatment response, blood count and liver enzyme checks, and imaging diagnostics at defined intervals to evaluate metastasis status. In patients with bone metastases or increased fracture risk, bone density and the use of bone-protective medications should also be assessed. Cardiac risk factors should be monitored during the course of therapy, as androgen deprivation is associated with an increased cardiovascular risk.